CN108936773A - Using ovalbumin-inulin as the preparation method of the microcapsules of wall material - Google Patents
Using ovalbumin-inulin as the preparation method of the microcapsules of wall material Download PDFInfo
- Publication number
- CN108936773A CN108936773A CN201810718163.1A CN201810718163A CN108936773A CN 108936773 A CN108936773 A CN 108936773A CN 201810718163 A CN201810718163 A CN 201810718163A CN 108936773 A CN108936773 A CN 108936773A
- Authority
- CN
- China
- Prior art keywords
- ovalbumin
- inulin
- wall material
- microcapsules
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001202 Inulin Polymers 0.000 title claims abstract description 74
- 229940029339 inulin Drugs 0.000 title claims abstract description 74
- 239000000463 material Substances 0.000 title claims abstract description 59
- 239000003094 microcapsule Substances 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 42
- 108010058846 Ovalbumin Proteins 0.000 claims abstract description 35
- 239000011162 core material Substances 0.000 claims abstract description 35
- 229940092253 ovalbumin Drugs 0.000 claims abstract description 35
- 239000007788 liquid Substances 0.000 claims abstract description 20
- 239000006185 dispersion Substances 0.000 claims abstract description 17
- 238000013019 agitation Methods 0.000 claims abstract description 16
- 239000000243 solution Substances 0.000 claims abstract description 15
- 239000011259 mixed solution Substances 0.000 claims abstract description 14
- 210000003022 colostrum Anatomy 0.000 claims abstract description 8
- 235000021277 colostrum Nutrition 0.000 claims abstract description 8
- 238000001694 spray drying Methods 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000008187 granular material Substances 0.000 claims abstract description 6
- 238000010008 shearing Methods 0.000 claims abstract description 5
- 239000000654 additive Substances 0.000 claims description 27
- 230000000996 additive effect Effects 0.000 claims description 27
- 108010000912 Egg Proteins Proteins 0.000 claims description 4
- 102000002322 Egg Proteins Human genes 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 18
- 238000006243 chemical reaction Methods 0.000 abstract description 13
- 239000011258 core-shell material Substances 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 6
- 238000013268 sustained release Methods 0.000 abstract description 5
- 239000012730 sustained-release form Substances 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 description 8
- 210000004051 gastric juice Anatomy 0.000 description 7
- 238000005320 surfactant adsorption Methods 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 3
- 235000007516 Chrysanthemum Nutrition 0.000 description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- -1 phytosterol etc. Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of using ovalbumin-inulin as the preparation method of the microcapsules of wall material, solves the problems, such as that existing microcapsule core shell structure stability is to be improved, functional insufficient.Technical solution is that (1) is soluble in water by ovalbumin, obtains ovalbumin dispersion liquid after carrying out magnetic agitation；(2) inulin is added into the ovalbumin dispersion liquid, is ultrasonically treated after magnetic agitation, obtained ovalbumin-inulin solution；(3) oiliness core material is added in the ovalbumin-inulin solution, obtains mixed solution；(4) mixed solution is placed in shearing under high speed shear instrument and obtains colostrum, then high pressure microjet homogeneous is multiple, and finally spray drying obtains microcapsule granule.Present invention process is simple, core-shell structure is stable, and had good sustained release effect absorbs beneficial to human consumption, has both health-care effect, and embedding rate, conversion ratio, effective percentage, bioactivity are good.
Description
Technical field
It is specifically a kind of using ovalbumin-inulin as the micro- of wall material the present invention relates to a kind of microcapsule preparation method
The preparation method of capsule.
Background technique
Microencapsulation technology, abbreviation microcapsule method, is usually made of two parts, that is, the core material and outside being embedded are coated
Wall material is the modern industry new and high technology to grow up in recent years, can be widely applied to weaving, fragrance, cosmetics, print
The fields such as dye, food.Its principle is exactly the microencapsulation being embedded in solid, liquid or gas material in terms of micron or nanometer
In, and the expected release for the material that is embedded is controlled under certain conditions.At present microencapsulation technology food, medicine, fragrance,
The industries such as dyestuff are used widely, it is known that the wall material of microcapsules is the key that microencapsulation technology, good wall material one
Aspect, which can be played on the good protection of core material, and homeostasis is not easy is influenced by external environment and decomposes denaturation, keeps its biology living
Property reaches larger reserving degree or raising, on the other hand can also make to embed by the control of delivery mode, time, speed and amount
Object biological function is preferably played.The raw material for making microcapsule wall material all the time has single protein, sodium alginate, shell
Glycan, gelatin, porous-starch etc. also have compounding for protein and polysaccharide.For oiliness core material, usually wrapped with aqua
Wrap up in the microcapsules to form oil-in-water structure, as wall material selection when, have the following problems: (1) wall material of single protide due to
The reason stability that hydrophily is weaker and shell thickness is relatively thin is poor, and extraneous poor environment can destroy embedded object；(2) due to embedding
Effect is poor, to influence the bioactivity of core material, reduces human absorptivity；(3) due to being formed between single protein macromolecule
Shell the reason of there are larger gaps, shell structurre is relatively thin, cannot achieve small enteric release, and sustained release effect truly is not achieved
Fruit.(4) selection of shell structurre only considers harmless to human body or animal, does not consider the health-care effect of deep layer further.
Summary of the invention
The purpose of the present invention is to solve above-mentioned technical problem, a kind of simple process is provided, core-shell structure is stablized, sustained release
Effect is good, absorbs beneficial to human consumption, has both health-care effect, the good albumen of embedding rate, conversion ratio, effective percentage, bioactivity
Albumen-inulin microcapsules preparation method.
Technical solution comprising the following specific steps
(1) ovalbumin is soluble in water, ovalbumin dispersion liquid is obtained after carrying out magnetic agitation；
(2) inulin is added into the ovalbumin dispersion liquid, is ultrasonically treated after magnetic agitation, obtained albumen egg
White-inulin solution；
(3) oiliness core material is added in the ovalbumin-inulin solution, obtains mixed solution；
(4) mixed solution is placed in shearing under high speed shear instrument and obtains colostrum, then high pressure microjet homogeneous is more
Secondary, finally spray drying obtains microcapsule granule.
In the step (1), egg protein concentration is 1.0-1.4%w/w in ovalbumin dispersion liquid.
In the step (2), inulin concentration is 1.0-1.4%w/w in the ovalbumin-inulin solution.
In the step (2), magnetic agitation frequency is 30-40rpm/min, ultrasonic intensity 180-200W/cm2, surpass
The sound time is 1-2 hours.
In the step (3), the additive amount additive amount of the medium oil core material of mixed solution is 5-10%w/w.
In the step (4), the revolving speed of the high speed shear instrument is 20000-25000rpm/min, shear time 1-
3min, control high pressure microjet homogeneous pressure is 11-13kPa.
In the step (4), spray drying condition are as follows: inlet air temperature is 170-190 DEG C, and leaving air temp is 85-90 DEG C, into
Stream speed is 500-600ml/h.
For the problems in background technique, inventor has made intensive studies the wall material of existing core-shell structure, by ovum
Albumin is compounded with inulin, and inulin is a kind of functional oligofructose and a kind of soluble dietary fiber, and having improves enteron aisle
Function, body from lacking of proper care and geriatric disease is helpful to preventing,, can be under the cavitation effect of ultrasound due to not charged
Physical bond occurs for protein, therefore, is ultrasonically treated after inulin is added in ovalbumin dispersion liquid, can be formed good
Emulsifier, be added oiliness core material when, ovalbumin be adsorbed on oiliness core surfaces formed core-shell structure emulsion droplet when, due to chrysanthemum
Powder molecular weight is small, can enter the gap between protein molecular, under the cavitation of ultrasound, and itself has certain coagulate
Colloidality, so will form fine and close firm shell, to construct stable core-shell structure.This stable core-shell structure is on the one hand
The success rate and stability to embedded object encapsulating can be improved, also further protect the bioactivity of embedded object；On the other hand, table
The smooth no recess in face, shell is thick and solid, and this wall material overwhelming majority reaches slow release effect in small enteric release.
Egg protein concentration is preferably 1.0-1.4%w/w1.2%w/w in the ovalbumin dispersion liquid, the albumen egg
Inulin concentration is 1.0-1.4%w/w in white-inulin solution., the conversion ratio and bioactivity of embedded object can be excessively reduced, and
Increase cost, it is very few to reduce embedding rate, increase the loss of oiliness core material.
Step (2) first carries out magnetic agitation, so that ovalbumin and inulin sufficiently dissolve, then carries out being ultrasonically treated again molten
Mixed solution after solution can make albumen and inulin combine closely under the cavitation of ultrasound in this way, increase its hydrophilic group
With the number of hydrophobic group, therefore its emulsion emulsifiers is improved, the preferably described magnetic agitation frequency is 30-40rpm/min, ultrasound
Intensity of wave is 180-200W/cm2, ultrasonic time is 1.5-2 hours.
The additive amount of the medium oil core material of step (3) mixed solution is preferably 10%w/w, compared to wall material, oiliness core
The additive amount of material is preferably controlled in 10%w/w, the emulsibility and stability of lotion can be excessively reduced, to reduce microcapsule wall material
Quality, the very few loss that will increase wall material raw material increases cost from another point of view.
Colostrum is obtained in step (4) mixed solution elder generation high speed shear, then high pressure microjet homogeneous is multiple, micro- using high pressure
Jet stream confrontation colostrum carry out second emulsifying, come into full contact with emulsifier with oiliness core material, thus reach improve emulsibility and surely
Qualitative purpose.
The oiliness core material, which refers to for liposoluble substance (core material) to be dissolved in oil-based solvent, to be made, the liposoluble substance
(core material) can enumerate curcumin, vitamin D, tocopherol, phytosterol etc., and medium chain triglyceride can be used in the oil-based solvent
The preparation method of three esters, rapeseed oil, peanut oil, corn oil etc., oiliness core material can be with reference to existing state of the art.
The method of the present invention is simple, easy to operate, easily controllable, compound as wall material using ovalbumin and inulin, has and takes
Same synergistic effect can form stable core-shell structure, and had good sustained release effect absorbs beneficial to human consumption, has both health-care effect, embed
Rate, conversion ratio, effective percentage, bioactivity are good.
Detailed description of the invention
Fig. 1 is the encapsulation rate of embedded object in the microcapsules of different inulin additive amounts；
Fig. 2 is embedded object utilization rate in the microcapsules of different inulin additive amounts；
Fig. 3 is the SURFACTANT ADSORPTION amount of the microcapsule wall material of different inulin additive amounts；
Fig. 4 is the absorption that the microcapsules of different inulin additive amounts simulate unsaturated fatty acid in digestion in vitro；
Fig. 5 is the microstructure of the microcapsule wall material of different inulin additive amounts, and wherein Fig. 5 a is the micro- glue of single ovalbumin
The microstructure of cyst wall material；Fig. 5 a is the microstructure that inulin additive amount is 1.0%w/w microcapsule wall material；Fig. 5 c adds for inulin
Dosage is the microstructure of 1.2%w/w microcapsule wall material；Fig. 5 d is that inulin additive amount is the microcosmic of 1.4%w/w microcapsule wall material
Structure.
Specific embodiment
The preparation of oiliness core material:
The preparation of microcapsules core material: 15% (w/v) glutathione aqueous solution is prepared, the triglycerides of phase homogenous quantities is added to
In, 3% (w/w) soybean lecithin is added as emulsifier, the high speed dispersion 4min under 12000r/min is made W/O lotion, obtains
Oiliness core material to glutathione microcapsules core material as following embodiments.
Embodiment 1 is a kind of using ovalbumin and inulin as the novel microcapsule wall material preparation method of wall material, and specific steps are such as
Under:
(1) ovalbumin is soluble in water, ovalbumin dispersion liquid is obtained after carrying out magnetic agitation, makes the ratio of ovalbumin
Example is 1.0%w/w；
(2) inulin is added to the ovalbumin dispersion liquid, the additive amount of inulin is 1.0%w/w, and magnetic agitation frequency is
30rpm/min, ultrasonic intensity 180W/cm2, ultrasonic time is 1 hour.；
(4) oiliness core material is added in the ovalbumin-inulin solution, additional amount 5%w/w, it is molten obtains mixing
Liquid；
(5) ovalbumin-inulin and oiliness core material mixed solution shearing 1min under high speed shear instrument is placed in obtain
To colostrum, revolving speed 20000rpm/min, then in the case where circulating in pressure and being 11kPa, high pressure microjet homogeneous is three times.
It (6) is 170 DEG C in inlet air temperature by the ovalbumin-inulin and triglycerides mixed emulsion, leaving air temp
It is 85 DEG C, under conditions of control feed flow rate is 500ml/h, spray drying obtains microcapsule granule.
Microcapsule wall material is up to 90.32% to the embedding rate of oiliness core material, and surfactant adsorption amount reaches
2.86mg/m2, and the embedded object conversion ratio under this wall material reaches 62.71%, effective percentage reaches 72.39%, bioactivity and reach
45.39%；Burst size is 21.43% in simulate the gastric juice, and burst size is 89.90% in simulated intestinal fluid, and extreme portions are in small intestine
In be digested absorption, small part discharges under one's belt, avoids embedded object from losing activity in severe gastric environment, more protects
Embedded object is digested.
Embodiment 2 is a kind of using ovalbumin and inulin as the novel microcapsule wall material preparation method of wall material, and specific steps are such as
Under:
(1) ovalbumin is soluble in water, ovalbumin dispersion liquid is obtained after carrying out magnetic agitation, makes the ratio of ovalbumin
Example is 1.2%w/w；
(2) inulin is added to the ovalbumin dispersion liquid, the additive amount of inulin is 1.2%w/w, and magnetic agitation frequency is
40rpm/min, ultrasonic intensity 200W/cm2, ultrasonic time is 2 hours.；
(4) oiliness core material is added in the ovalbumin-inulin solution, additional amount 10%w/w, it is molten obtains mixing
Liquid；
(5) ovalbumin-inulin and oiliness core material mixed solution are placed under high speed shear instrument and shear 1.5min
Obtain colostrum, revolving speed 25000rpm/min, then high pressure microjet homogeneous is three times in the case where circulating in pressure and being 12kPa.
It (6) is 190 DEG C in inlet air temperature by the ovalbumin-inulin and triglycerides mixed emulsion, leaving air temp
It is 85 DEG C, under conditions of control feed flow rate is 600ml/h, spray drying obtains microcapsule granule.
Microcapsule wall material is up to 94.16% to the embedding rate of oiliness core material, and surfactant adsorption amount reaches
3.97mg/m2, and the embedded object conversion ratio under this wall material reaches 71.76%, effective percentage reaches 82.31%, bioactivity and reach
59.07%；Burst size is 18.32% in simulate the gastric juice, and burst size is 95.53% in simulated intestinal fluid, and the overwhelming majority is in small intestine
In be digested absorption, few part discharges under one's belt, avoids embedded object from losing activity in severe gastric environment, more protects
Embedded object has been protected to be digested.
Embodiment 3 is a kind of using ovalbumin and inulin as the novel microcapsule wall material preparation method of wall material, and specific steps are such as
Under:
(1) ovalbumin is soluble in water, ovalbumin dispersion liquid is obtained after carrying out magnetic agitation, makes the ratio of ovalbumin
Example is 1.4%w/w；
(2) inulin is added to the ovalbumin dispersion liquid, the additive amount of inulin is 1.4%w/w, and magnetic agitation frequency is
35rpm/min, ultrasonic intensity 190W/cm2, ultrasonic time is 1.5 hours.；
(4) oiliness core material is added in the ovalbumin-inulin solution, additional amount 10%w/w, it is molten obtains mixing
Liquid；
(5) ovalbumin-inulin and oiliness core material mixed solution shearing 3min under high speed shear instrument is placed in obtain
To colostrum, revolving speed 23000rpm/min, then in the case where circulating in pressure and being 13kPa, high pressure microjet homogeneous is three times.
It (6) is 180 DEG C in inlet air temperature by the ovalbumin-inulin and triglycerides mixed emulsion, leaving air temp
It is 90 DEG C, under conditions of control feed flow rate is 600ml/h, spray drying obtains microcapsule granule.
Microcapsule wall material is up to 87.96% to the embedding rate of oiliness core material, and surfactant adsorption amount reaches
3.47mg/m2, and the embedded object conversion ratio under this wall material reaches 69.51%, effective percentage reaches 77.21%, bioactivity and reach
53.67%；Burst size is 24.72% in simulate the gastric juice, and burst size is 92.11% in simulated intestinal fluid, and extreme portions are in small intestine
In be digested absorption, small part discharges under one's belt, avoids embedded object from losing activity in severe gastric environment, more protects
Embedded object is digested.
Comparative example 1
In addition to not adding ovalbumin, remaining is the same as embodiment 2.
Microcapsule wall material is up to 34.12% to the embedding rate of oiliness core material, and surfactant adsorption amount reaches
0.29mg/m2, and the embedded object conversion ratio under this wall material reaches 41.23%, effective percentage reaches 32.32%, bioactivity and reach
13.32%；Burst size is 51.32% in simulate the gastric juice, and burst size is 72.53% in simulated intestinal fluid, and the overwhelming majority is in gastric juice
Middle release, causes embedded object to inactivate, and unfavorable human consumption absorbs.
Comparative example 2
In addition to not adding inulin, remaining is the same as embodiment 2.
Microcapsule wall material is up to 73.12% to the embedding rate of oiliness core material, and surfactant adsorption amount reaches
1.16mg/m2, and the embedded object conversion ratio under this wall material reaches 51.23%, effective percentage reaches 62.32%, bioactivity and reach
31.92%；Burst size is 41.32% in simulate the gastric juice, and burst size is 68.53% in simulated intestinal fluid, and significant portion is in gastric juice
Middle release, causes embedded object to inactivate, and unfavorable human consumption absorbs.
Fig. 1 is the encapsulation rate of embedded object in the microcapsules of different inulin additive amounts, as can be seen from Figure adding when inulin
Dosage is 1.2%w/w, this wall material has highest embedding rate, is made full use of to embedded object；Fig. 2 is different inulin additive amounts
Microcapsules in embedded object utilization rate, as can be seen from Figure when the additive amount of inulin be 1.2%w/w, the conversion ratio of this wall material,
Efficient and bioactivity highest guarantees that embedded object is absorbed by the body with best activity；Fig. 3 is micro- glue of different inulin additive amounts
The SURFACTANT ADSORPTION amount of cyst wall material, as can be seen from Figure when the additive amount of inulin is 1.2%w/w, this wall material has most
Big surface excess consolidates shell core thick and solid, and embedded object is largely protected not caused to inactivate by external condition influence；Fig. 4
It is that the microcapsules of different inulin additive amounts simulate the absorption of unsaturated fatty acid in digestion in vitro, works as chrysanthemum as can be seen from Figure
The additive amount of powder is 1.2%w/w, and the embedded object overwhelming majority of this wall material is digested absorption in small intestine, and few part is under one's belt
Release, avoids embedded object from losing activity in severe gastric environment, more embedded object is protected to be digested；Figure
5 be the microstructure of the microcapsule wall material of different inulin additive amounts, and wherein Fig. 5 a is the micro- of single ovalbumin microcapsule wall material
See structure；Fig. 5 b is the microstructure that inulin additive amount is 1.0%w/w microcapsule wall material；Fig. 5 c is that inulin additive amount is 1.2%
The microstructure of w/w microcapsule wall material；Fig. 5 d is the microstructure that inulin additive amount is 1.4%w/w microcapsule wall material, by figure
It can be seen that when inulin additive amount be 1.2%w/w, surface is smooth, and shell is firm thick and solid, full grains without recess, and with than
It is compared compared with example 1, ovalbumin-inulin composite micro-capsule wall material has larger in embedding rate, conversion ratio, effective percentage, bioactivity
It improves, and comparative example 1 discharges under one's belt in the overwhelming majority, is unfavorable for absorption of human body.And compared with comparative example 2, ovalbumin-
Inulin composite micro-capsule wall material all improves a lot in conversion ratio, effective percentage, bioactivity, slightly improves on encapsulation rate, and
Comparative example 2 discharges under one's belt in major part, is unfavorable for absorption of human body.Therefore the micro capsule technology letter of preparation of the embodiment of the present invention
Single, core-shell structure is stablized, and had good sustained release effect absorbs beneficial to human consumption, has both health-care effect, embedding rate, conversion ratio, effectively
Rate, bioactivity are good.
Claims (7)
1. a kind of using ovalbumin-inulin as the preparation method of the microcapsules of wall material, it is characterised in that, including walk in detail below
It is rapid:
(1) ovalbumin is soluble in water, ovalbumin dispersion liquid is obtained after carrying out magnetic agitation；
(2) inulin is added into the ovalbumin dispersion liquid, is ultrasonically treated after magnetic agitation, obtained ovalbumin-
Inulin solution；
(3) oiliness core material is added in the ovalbumin-inulin solution, obtains mixed solution；
(4) mixed solution is placed in shearing under high speed shear instrument and obtains colostrum, then high pressure microjet homogeneous is multiple, most
Spray drying obtains microcapsule granule afterwards.
2. as described in claim 1 using ovalbumin-inulin as the preparation method of the microcapsules of wall material, which is characterized in that institute
It states in step (1), egg protein concentration is 1.0-1.4%w/w in ovalbumin dispersion liquid.
3. ovalbumin as described in claim 1-inulin microcapsules preparation method, which is characterized in that the step (2)
In, inulin concentration is 1.0-1.4%w/w in the ovalbumin-inulin solution.
4. as claimed in claim 1 or 3 using ovalbumin-inulin as the preparation method of the microcapsules of wall material, which is characterized in that
In the step (2), magnetic agitation frequency is 30-40rpm/min, ultrasonic intensity 180-200W/cm2, ultrasonic time is
1-2 hours.
5. as described in claim 1 using ovalbumin-inulin as the preparation method of the microcapsules of wall material, which is characterized in that institute
It states in step (3), the additive amount of the medium oil core material of mixed solution is 5-10%w/w.
6. as described in claim 1 using ovalbumin-inulin as the preparation method of the microcapsules of wall material, which is characterized in that institute
It states in step (4), the revolving speed of the high speed shear instrument is 20000-25000rpm/min, shear time 1-3min, and control is high
Pressing microjet homogeneous pressure is 11-13kPa.
7. as described in claim 1 or 6 using ovalbumin-inulin as the preparation method of the microcapsules of wall material, which is characterized in that
In the step (4), spray drying condition are as follows: inlet air temperature is 170-190 DEG C, and leaving air temp is 85-90 DEG C, and feed flow rate is
500-600ml/h。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810718163.1A CN108936773B (en) | 2018-07-03 | 2018-07-03 | Preparation method of microcapsule with ovalbumin-inulin as wall material |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810718163.1A CN108936773B (en) | 2018-07-03 | 2018-07-03 | Preparation method of microcapsule with ovalbumin-inulin as wall material |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108936773A true CN108936773A (en) | 2018-12-07 |
| CN108936773B CN108936773B (en) | 2020-08-14 |
Family
ID=64485155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810718163.1A Active CN108936773B (en) | 2018-07-03 | 2018-07-03 | Preparation method of microcapsule with ovalbumin-inulin as wall material |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108936773B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110698689A (en) * | 2019-11-21 | 2020-01-17 | 大连民族大学 | Preparation method of ovalbumin glycosylation reaction surfactant |
| CN111480848A (en) * | 2020-05-07 | 2020-08-04 | 河北东康乳业有限公司 | Preparation method of high-embedding-rate multi-layer wall material fat powder |
| CN111635824A (en) * | 2020-05-14 | 2020-09-08 | 湖北旭东实业有限公司 | Modification method of ovalbumin and application of ovalbumin in pomegranate seed oil protection |
| CN116686993A (en) * | 2023-06-28 | 2023-09-05 | 嘉必优生物技术（武汉）股份有限公司 | Preparation method of high-oil-carrying polyunsaturated fatty acid oil microcapsule |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101564168A (en) * | 2009-06-09 | 2009-10-28 | 天津科技大学 | Nutrient energy bar with energy slow release function and preparation method thereof |
| CN101810336A (en) * | 2010-04-30 | 2010-08-25 | 广东仙乐制药有限公司 | Chewable soft capsules and method for preparing same |
| CN102210373A (en) * | 2011-04-08 | 2011-10-12 | 中国农业大学 | Microencapsulated protein polypeptide and preparation method thereof |
| CN104757138A (en) * | 2015-04-28 | 2015-07-08 | 东北农业大学 | Preparation method for microencapsulation whey protein hydrolysate with prebiotics and whey protein concentrate being wall materials |
| CN105077244A (en) * | 2015-08-26 | 2015-11-25 | 江南大学 | Preparation method of lycopene microcapsules |
-
2018
- 2018-07-03 CN CN201810718163.1A patent/CN108936773B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101564168A (en) * | 2009-06-09 | 2009-10-28 | 天津科技大学 | Nutrient energy bar with energy slow release function and preparation method thereof |
| CN101810336A (en) * | 2010-04-30 | 2010-08-25 | 广东仙乐制药有限公司 | Chewable soft capsules and method for preparing same |
| CN102210373A (en) * | 2011-04-08 | 2011-10-12 | 中国农业大学 | Microencapsulated protein polypeptide and preparation method thereof |
| CN104757138A (en) * | 2015-04-28 | 2015-07-08 | 东北农业大学 | Preparation method for microencapsulation whey protein hydrolysate with prebiotics and whey protein concentrate being wall materials |
| CN105077244A (en) * | 2015-08-26 | 2015-11-25 | 江南大学 | Preparation method of lycopene microcapsules |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110698689A (en) * | 2019-11-21 | 2020-01-17 | 大连民族大学 | Preparation method of ovalbumin glycosylation reaction surfactant |
| CN111480848A (en) * | 2020-05-07 | 2020-08-04 | 河北东康乳业有限公司 | Preparation method of high-embedding-rate multi-layer wall material fat powder |
| CN111635824A (en) * | 2020-05-14 | 2020-09-08 | 湖北旭东实业有限公司 | Modification method of ovalbumin and application of ovalbumin in pomegranate seed oil protection |
| CN111635824B (en) * | 2020-05-14 | 2023-06-20 | 武汉旭东食品有限公司 | Modification method of ovalbumin and application of ovalbumin in protection of pomegranate seed oil |
| CN116686993A (en) * | 2023-06-28 | 2023-09-05 | 嘉必优生物技术（武汉）股份有限公司 | Preparation method of high-oil-carrying polyunsaturated fatty acid oil microcapsule |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108936773B (en) | 2020-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108936773A (en) | Using ovalbumin-inulin as the preparation method of the microcapsules of wall material | |
| Sarabandi et al. | Spray-drying encapsulation of protein hydrolysates and bioactive peptides: Opportunities and challenges | |
| US11123291B2 (en) | Methods and systems for forming multi-layered particles | |
| US6969530B1 (en) | Microcapsules and emulsions containing low bloom gelatin and methods of making and using thereof | |
| EP1846153B1 (en) | Microcapsules and emulsions containing low bloom gelatin and methods of making and using thereof | |
| CN107362154B (en) | Microcapsules with improved shell | |
| KR100811284B1 (en) | Encapsulated agglomeration of microcapsules and method for the preparation thereof | |
| JP2542697B2 (en) | Powder preparation | |
| CN101288662B (en) | Xanthophyll micro-capsule and its preparation method | |
| CN100334962C (en) | Microcapsules and oral compositions containing the same | |
| Gharibzahedi et al. | New trends in the microencapsulation of functional fatty acid‐rich oils using transglutaminase catalyzed crosslinking | |
| CN105533691B (en) | A kind of micro/nano level fish oil/algae oil microcapsules and its preparation process | |
| JP5419704B2 (en) | Method for producing microcapsules using solid fat | |
| US20090238885A1 (en) | Protein encapsulated particles | |
| JP2010515455A (en) | Vegetarian microcapsules | |
| JP2005500157A (en) | Coated stable microcapsule | |
| EP1790235A1 (en) | Method for producing capsinoid-containing microcapsule | |
| CN107486111B (en) | A kind of preparation method of multilayer embedding microcapsules | |
| Liu et al. | Egg white protein-based delivery system for bioactive substances: A review | |
| Zhou et al. | Food-grade systems for delivery of DHA and EPA: Opportunities, fabrication, characterization and future perspectives | |
| KR100871050B1 (en) | Preparation method of microcapsule comprising coenzyme Q1O | |
| WO2014130801A1 (en) | Enteric delivery of functional ingredients for animals | |
| EP2490555A1 (en) | Barrier composition | |
| Anbudhasan et al. | Development of omega 3 fatty acid enriched stable functional foods: Challenges and options | |
| TW201446150A (en) | Enteric delivery of functional ingredients suitable for hot comestible applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200731 Address after: No.33, innovation Avenue, Dongxihu District, Wuhan City, Hubei Province Applicant after: Hubei Xudong Industrial Co.,Ltd. Address before: 430068, No. 28, South Eru, Hongshan District, Hubei, Wuhan Applicant before: HUBEI University OF TECHNOLOGY |
|
| TA01 | Transfer of patent application right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230329 Address after: 430040 No.55, Qixiong Road, Wujiashan, Dongxihu District, Wuhan City, Hubei Province Patentee after: WUHAN XUDONG FOOD Co.,Ltd. Address before: No. 33 Gexin Avenue, Dongxihu District, Wuhan City, Hubei Province, 430040 Patentee before: Hubei Xudong Industrial Co.,Ltd. |
|
| TR01 | Transfer of patent right |